Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Levy, Laura Evans, A. Rhodes (2018)
The Surviving Sepsis Campaign Bundle: 2018 Update.Critical Care Medicine
L. Busse, Xueyuan Wang, Divya Chalikonda, Kevin Finkel, A. Khanna, H. Szerlip, David Yoo, S. Dana, L. Chawla (2017)
Clinical Experience With IV Angiotensin II Administration: A Systematic Review of SafetyCritical Care Medicine, 45
Vaughan Thomas, Michael Nielsen (1991)
Administration of angiotensin II in refractory septic shock.Critical care medicine, 19 8
E. Bassi, Marcelo Park, L. Azevedo (2013)
Therapeutic Strategies for High-Dose Vasopressor-Dependent ShockCritical Care Research and Practice, 2013
R. Wiesner, E. Edwards, R. Freeman, A. Harper, R. Kim, P. Kamath, W. Kremers, J. Lake, T. Howard, R. Merion, R. Wolfe, R. Krom (2003)
Model for end-stage liver disease (MELD) and allocation of donor livers.Gastroenterology, 124 1
F. Ferreira, D. Bota, A. Bross, C. Mélot, J. Vincent (2001)
Serial evaluation of the SOFA score to predict outcome in critically ill patients.JAMA, 286 14
F. Bonanno (2011)
Clinical pathology of the shock syndromesJournal of Emergencies, Trauma and Shock, 4
R. Dellinger, M. Levy, A. Rhodes, D. Annane, H. Gerlach, S. Opal, J. Sevransky, C. Sprung, I. Douglas, R. Jaeschke, T. Osborn, M. Nunnally, S. Townsend, K. Reinhart, R. Kleinpell, D. Angus, C. Deutschman, F. Machado, G. Rubenfeld, S. Webb, R. Beale, J. Vincent, R. Moreno (2013)
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock 2012Critical Care Medicine, 41
L. Chawla, L. Busse, E. Brasha-Mitchell, D. Davison, Jacqueline Honiq, Ziyad Alotaibi, M. Seneff (2014)
Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot studyCritical Care, 18
G. Vliegen, K. Kehoe, An Bracke, Emilie Hert, R. Verkerk, E. Fransen, B. Jongers, E. Peters, A. Lambeir, S. Kumar-Singh, P. Pickkers, P. Jorens, I. Meester (2020)
Dysregulated activities of proline-specific enzymes in septic shock patients (sepsis-2)PLoS ONE, 15
M. Yunge, A. Petros (2000)
Angiotensin for septic shock unresponsive to noradrenalineArchives of Disease in Childhood, 82
LW Busse, XS Wang, DM Chalikonda (2017)
Clinical experience with intravenous angiotensin II administration: a systematic review of safetyCrit Care Med, 45
J. Vincent, R. Moreno, J. Takala, S. Willatts, A. Mendonça, H. Bruining, C. Reinhart, P. Suter, L. Thijs (1996)
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failureIntensive Care Medicine, 22
Ronald Magness, Kay Cox, Charles Rosenfeld, Norman Gant (1994)
Angiotensin II metabolic clearance rate and pressor responses in nonpregnant and pregnant women.American journal of obstetrics and gynecology, 171 3
L. Busse, M. McCurdy, Osman Ali, Anna Hall, Huaizhen Chen, M. Ostermann (2017)
The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literatureCritical Care, 21
P. Balakumar, G. Jagadeesh (2014)
A century old renin-angiotensin system still grows with endless possibilities: AT1 receptor signaling cascades in cardiovascular physiopathology.Cellular signalling, 26 10
P. Admiraal, A. Danser, M Jong, H. Pieterman, F. Derkx, M. Schalekamp (1993)
Regional angiotensin II production in essential hypertension and renal artery stenosis.Hypertension, 21 2
D. Brand, P. Patrick, J. Berger, Mediha Ibrahim, A. Matela, S. Upadhyay, P. Spiegler (2017)
Intensity of Vasopressor Therapy for Septic Shock and the Risk of In-Hospital Death.Journal of pain and symptom management, 53 5
(2000)
Prothrombin effects of angiotensin
J. Gall, S. Lemeshow, F. Saulnier (1993)
A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study.JAMA, 270 24
A. Khanna, S. English, Xueyuan Wang, Kealy Ham, J. Tumlin, H. Szerlip, L. Busse, L. Altaweel, T. Albertson, C. Mackey, M. McCurdy, David Boldt, Stefan Chock, P. Young, K. Krell, R. Wunderink, M. Ostermann, R. Murugan, M. Gong, R. Panwar, J. Hästbacka, R. Favory, B. Venkatesh, B. Thompson, R. Bellomo, J. Jensen, J. Jensen, Stew Kroll, L. Chawla, G. Tidmarsh, G. Tidmarsh, G. Tidmarsh, A. Deane (2017)
Angiotensin II for the Treatment of Vasodilatory ShockThe New England Journal of Medicine, 377
A. Rhodes, Laura Evans, W. Alhazzani, Mitchell Levy, M. Antonelli, R. Ferrer, Anand Kumar, J. Sevransky, C. Sprung, M. Nunnally, B. Rochwerg, G. Rubenfeld, D. Angus, D. Annane, Richard Beale, Geoffrey Bellinghan, Gordon Bernard, J. Chiche, C. Coopersmith, Daniel Backer, Craig French, S. Fujishima, H. Gerlach, Jorge Hidalgo, S. Hollenberg, Alan Jones, Dilip Karnad, R. Kleinpell, Younsuk Koh, Thiago Lisboa, Flavia Machado, John Marini, John Marshall, J. Mazuski, L. McIntyre, Anthony McLean, S. Mehta, Rui Moreno, J. Myburgh, P. Navalesi, O. Nishida, Tiffany Osborn, A. Perner, Colleen Plunkett, M. Ranieri, Christa Schorr, Maureen Seckel, Christopher Seymour, L. Shieh, Khalid Shukri, Steven Simpson, M. Singer, B. Thompson, S. Townsend, Thomas Poll, J. Vincent, W. Wiersinga, Janice Zimmerman, R. Dellinger (2017)
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016Intensive Care Medicine, 43
M. Levy, Laura Evans, A. Rhodes (2018)
The Surviving Sepsis Campaign Bundle: 2018 updateIntensive Care Medicine, 44
D. Batlle, J. Wysocki, M. Soler, K. Ranganath (2012)
Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy.Kidney international, 81 6
J. Vincent, D. Backer (2013)
Circulatory shock.The New England journal of medicine, 369 18
J. Velez (2009)
The importance of the intrarenal renin–angiotensin systemNature Clinical Practice Nephrology, 5
Stanley Bradley, Barbara Parker (1941)
THE HEMODYNAMIC EFFECTS OF ANGIOTONIN IN NORMAL MAN.The Journal of clinical investigation, 20 6
D. Wong, W. Knaus (1991)
Predicting outcome in critical care: the current status of the APACHE prognostic scoring systemCanadian Journal of Anaesthesia, 38
C. Pastor, D. Morel, S. Whiteley, J. Dade, J. Stewart, G. Wray, J. Coakley (1996)
Treatment of hypotension in septic shockThe Lancet, 347
Mark Williams, J. Russell (2019)
Terlipressin or norepinephrine in septic shock: do we have the answer?Journal of thoracic disease, 11 Suppl 9
Distributive shock is a subset of shock marked by decreased systemic vascular resistance, organ hypoperfusion and altered oxygen extraction. Despite the use of intravenous fluids and either higher dose of catecholamines or other additional exogenous vasopressors to maintain blood pressure in the target range, the rate of mortality remains higher in patients with septic shock. Therefore, there is clearly an unmet need for additional safe and effective treatments. The use of angiotensin II to raise the mean arterial pressure (MAP) could provide additional therapy and the opportunity to evaluate a catecholamine-sparing effect by decreasing the dose of concomitant catecholamines while maintaining a target MAP. ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock phase 3; ClinicalTrials.gov number, NCT02338843) was an adequate and well-controlled trial. The primary endpoint was the rate of MAP response at hour 3 of treatment with study drug, defined as either a 10-mmHg increase from baseline in MAP or a MAP of at least 75 mmHg. The secondary endpoints were changes from baseline in Sequential Organ Failure Assessment (SOFA) scores (total and cardiovascular). Mortality was an exploratory endpoint. The trial provided substantial evidence of the effectiveness of angiotensin II in raising blood pressure over placebo in patients with distributive shock, while keeping catecholamine levels constant. There was no change in the secondary endpoint of total SOFA scores relative to placebo when catecholamine use was reduced in lieu of angiotensin II treatment. There was a slight decrease in the secondary endpoint of cardiovascular SOFA score relative to placebo during the catecholamine-sparing phase, reflecting the catecholamine-sparing effect. There was a consistent trend in decreased mortality relative to placebo over the 28-day study period. Based on the agreements emanating from the special protocol assessment to assess blood pressure effects, the data from this single study supported approval of angiotensin II by the Food and Drug Administration for marketing in the USA.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 25, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.